Literature DB >> 15066228

Hepatocellular carcinoma: epidemic and treatment.

Jill Allen1, Alan Venook.   

Abstract

Hepatocellular carcinoma remains a worldwide epidemic. Survival rates are poor; however, oncologists are able to offer regional therapies to those patients who present with early disease. Prevention through vaccination remains a mainstay of this epidemic. New staging systems that incorporate important information about tumor characteristics and liver disease improve our ability to prognosticate and treat these patients.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15066228     DOI： 10.1007/s11912-004-0047-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  57 in total

1.  Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.

Authors:  W Y Lau; T W Leung; S K Ho; M Chan; D Machin; J Lau; A T Chan; W Yeo; T S Mok; S C Yu; N W Leung; P J Johnson
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

Review 2.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

Review 3.  Preventive treatments for recurrence after curative resection of hepatocellular carcinoma--a literature review of randomized control trials.

Authors:  Hui-Chuan Sun; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

4.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

5.  Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis.

Authors:  Francis Y Yao
Journal:  J Clin Gastroenterol       Date:  2003 May-Jun       Impact factor: 3.062

Review 6.  Hepatitis B--an important public health issue.

Authors:  W C Maddrey
Journal:  Clin Lab       Date:  2001       Impact factor: 1.138

7.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts.

Authors:  Wei-Dong Jia; Ge-Liang Xu; Rong-Nan Xu; Hui-Chuan Sun; Lu Wang; Ji-Hai Yu; Jian Wang; Jian-Sheng Li; Zhi-Ming Zhai; Qiong Xue
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-14       Impact factor: 4.553

9.  ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model.

Authors:  Mitsuhiro Matsuo; Hiroaki Sakurai; Ikuo Saiki
Journal:  Mol Cancer Ther       Date:  2003-06       Impact factor: 6.261

10.  Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor.

Authors:  Ke-Qin Hu; Chang-Hong Yu; Yoshimitsu Mineyama; John D McCracken; Donald J Hillebrand; Mateen Hasan
Journal:  Int J Oncol       Date:  2003-04       Impact factor: 5.650
View more
  5 in total

1.  Current management of hepatocellular cancer.

Authors:  Bernardino Rampone; Beniamino Schiavone; Giuseppe Confuorto
Journal:  Curr Oncol Rep       Date:  2010-05       Impact factor: 5.075

2.  DNA repair gene XRCC3 Thr241Met polymorphism and hepatocellular carcinoma risk.

Authors:  Chenyang Duan; Wanli Zhang; Jiangfeng Lu; Huawen Wu; Mengying Liu; Wentao Zhu
Journal:  Tumour Biol       Date:  2013-07-04

Review 3.  Current management strategy of hepatocellular carcinoma.

Authors:  Bernardino Rampone; Beniamino Schiavone; Antonio Martino; Carmine Viviano; Giuseppe Confuorto
Journal:  World J Gastroenterol       Date:  2009-07-14       Impact factor: 5.742

4.  Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk.

Authors:  Long Lv; Ping Wang; Xiaoqing Zhou; Beicheng Sun
Journal:  Tumour Biol       Date:  2013-04-06

5.  Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and (18)F-FDG PET/CT in patients on waiting-list for liver transplantation.

Authors:  Samia Boussouar; Emmanuel Itti; Shih-Jui Lin; Thomas Decaens; Eva Evangelista; Melanie Chiaradia; Julia Chalaye; Laurence Baranes; Julien Calderaro; Alexis Laurent; Frederic Pigneur; Christophe Duvoux; Daniel Azoulay; Charlotte Costentin; Alain Rahmouni; Alain Luciani
Journal:  Cancer Imaging       Date:  2016-02-16       Impact factor: 3.909
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.